New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Go back to New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life| (NYSE: TAK) | Delayed: 18.95 +0.06 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.89 | 52 Week High | $0.55 | |||
| Open | $18.92 | 52 Week Low | $0.55 | |||
| Day High | $19.05 | P/E | N/A | |||
| Day Low | $18.81 | EPS | $-0.20 | |||
| Volume | 1,403,872 | |||||
